Attend virtual education event for gynecologic cancer care

March 24, 2022 Providence Cancer Institute of Oregon

Join Andrea Hardy, RN, BSN, Providence gynecologic oncology nurse care coordinator, on March 9 for Coping with Chemotherapy. This is a free, virtual educational event for gynecologic cancer patients and their caregivers presented by the Ovarian Cancer Alliance of Oregon & SW Washington in collaboration with Providence Cancer Institute of Oregon.

Andrea will help empower patients to take an active role in their own health care by helping them understand chemotherapy and its side effects, both physically and emotionally.

Topics will include:

Taking an active role in your care
Understanding chemotherapy
Most common types of chemotherapy, including immunotherapy and oral PARP inhibitors
Understanding and managing the side effects of chemotherapy
Communicating with your health care team

Event details

Wednesday, March 9, 2022

5:00 p.m. - 6:15 p.m. PT

Register here

About the presenter

Andrea Hardy, RN, BSN, is a Gynecologic Oncology Nurse Care Coordinator at Providence Cancer Institute of Oregon. She cares for patients with gynecologic cancer throughout their diagnosis, treatment, and survivorship. Among her various nursing services, Andrea provides patient education for symptom management over the course of treatments, starting with chemotherapy. This support helps to ease the journey into the unknown and empowers patients to participate in their own health care.

About the Providence Gynecologic Oncology Program

The Providence Gynecologic Cancer Program provides highly specialized care for patients diagnosed with ovarian, cervical, uterine, vaginal, vulvar and other female reproductive tract cancers, as well as pre-cancerous conditions. Patients receive advanced treatments, from robotic surgery to immunotherapy, with the opportunity to participate in clinical trials. To learn more, visit ProvidenceOregon.org/gyncancer.

Related resources

Gynecologic oncology care now available at Providence Cancer Institute

Clinical trial aims to help premenopausal women at risk for ovarian cancer

Phase II study of neoadjuvant combination therapy for ovarian cancer

Welcome to your journey for creating a healthier you

Attend virtual education event for gynecologic cancer care

Previous Article

Next Article

Attend virtual education event for gynecologic cancer care

Previous Article

Next Article

Other content in this Stream

Researchers at Providence Cancer Institute are exploring a range of innovative approaches to targeting human papillomavirus-positive head and neck squamous cell cancer.

In recognition of National Social Work Month, Darlene Corral, LCSW, shares a little insight into the importance of oncology social workers.

In honor of National Nutrition Month® Alyssa George, MA, RDN, program manager at Oncology Nutrition, Providence Cancer Institute, talks about the important connection between cancer and nutrition.

In a new clinical trial open at Providence Cancer Institute, the therapy IGM-8444 aims to promote apoptosis, potentially slowing down the growth of DR5-positive tumor cells.

Please revert to normal e-prescribing workflows and stop using paper prescriptions.

Two early phase trials available at Providence Cancer Institute to evaluate escalating doses of different potential cancer treatments in patients with advanced solid tumors.

The Food and Drug Administration has approved an adoptive cell therapy for adult patients with melanoma that has spread to other parts of the body (metastatic).

Supporting thousands of patients experiencing food insecurity, a converted space at Providence Gateway Internal Medicine clinic is filled with fresh fruits and vegetables, meat, milk, eggs and more.

Jamie Zilverberg, MSN, FNP, AOCNP, receives the prestigious 2024 Values in Action Award, the highest honor given at Providence St. Joseph Health.

In honor of International Day of Women and Girls in Science we highlight a researcher at Earle A. Chiles Research Institute, the research arm of Providence Cancer Institute.

Providence registered dietitian Christina Speaks, MS, RDN, LD, shares valuable information about food and common cancer myths.

New study evaluates immunotherapy in combination with other medications in people with endometrial cancer, and a phase I trial for people with AML assesses a non-engineered natural killer cell therapy

Providence and Regence have reached an agreement to continue care delivery services together.

"Within Reach: The Fight to Finish Cancer" follows patient participants and teams of researchers and clinicians at Providence Cancer Institute working to create a living drug for incurable cancers.

New articles co-authored by Dr. Rachel Sanborn feature amivantamab studies for people with NSCLC.

The Oregon Health Authority has selected the Portland, Oregon-based Center for Outcomes Research & Education (CORE) to create an evaluation design for Oregon's 2022-2027 1115 Medicaid waiver.

Highlights from 2023 events, achievements and advancements at Providence Cancer Institute.

Providence hematology oncologist and outdoors enthusiast Eric C. Anderson, M.D., shares his love of the Pacific Northwest and his philosophy of care for patients.

A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.

Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.